Category Archives: Disorders

Biotech, Business of Medicine, Diseases, Disorders, Drugs, Health Products, Healthcare Information, Healthcare Products, Healthcare Professionals, Healthcare Services, Healthcare Solutions, Medicine, Public Health, Society

Novartis, Lundbeck, and GSK Among Pharmaceutical Companies to Present at Patients as Partners Europe 2023

Leave a comment

NEW YORK, NY, United States, 13-Apr-2023 — /EPR HEALTHCARE NEWS/ — The Conference Forum announced that the 7th annual European Patients as Partners® in Clinical Research conference will return to London at the Thistle Hotel Marble Arch on June 12-13, 2023. The event will showcase the progress made by pharma R&D executives with input from patients on achieving greater representation in clinical research, building trust and engagement in communities, and building truly patient-centric R&D organizations.

“We are delighted to be back in person to offer an unparalleled opportunity to hear from pharma R&D and patient advocacy together on how patient involvement gets done to drive greater efficiencies in clinical research with better outcomes,” said Valerie Bowling, Executive Director, Patients as Partners in Clinical Research Europe.

A variety of pharmaceutical companies will report on the progress they’ve made engaging communities and partnering with patients. Sanofi will open with the evolution of patient-informed research and its impact on medicine development. Novartis will be speaking on the organization’s global approach to implementing systematic and consistent patient engagement across the medicine lifecycle with a focus on measurement.

Lundbeck will share how they are generating insights through engagement with patient communities and making patient input actionable for medicines development. CSL Behring will discuss how they are evaluating clinical research sites based on patient-focused principles.

Several companies, including Regeneron, the Center for BME Health and Sanofi, will discuss their progress in increasing diversity amongst underrepresented communities in clinical research. GSK will lead a session on understanding barriers to community engagement in clinical research.

Boehringer Ingelheim will discuss the company’s approach to engaging patients throughout the clinical trial and how to leverage those patient insights to improve the process. Alnylam Pharmaceuticals will share how the organization has developed a top-down approach to integrating the patient perspective.

The conference features incredible patient advocate representation, addressing the realities of underrepresented communities to better serve them. For the first time, Patients as Partners Europe will have a patient-led session on supporting mental health for patients in clinical research.

“I look forward to hearing from patients and industry colleagues about what matters most and what has the greatest impact when partnering with patients and their communities on our efforts to new therapeutic options available,” said Deirdre BeVard, SVP, R&D Strategic Operations, CSL Behring and Patients as Partners Europe co-chair.

Key topics for 2023 include:

  • The evolution of patient informed research
  • Increasing diversity in clinical research
  • Patient access to research through digital innovation
  • Understanding barriers to community engagement in clinical research
  • Turning patient insights into action
  • Navigating patient engagement and compliance
  • Mapping and how to measure patient engagement
  • Regulatory requirements and patient engagement in drug development

To learn more about the event, and a full overview of speakers, please click here (https://theconferenceforum.org/conferences/patients-as-partners-europe/overview/)

About Patients as Partners EU
Patients as Partners is co-produced with patients, industry, academia, government and nonprofit organizations to establish a well-rounded program that addresses the needs of all stakeholders seeking to implement and advance patient involvement across the entire clinical development continuum.

About the Conference Forum
The Conference Forum is a life science industry research firm that develops conferences primarily around how to get therapeutics to patients faster. They examine and challenge the complex ecosystem of drug development and delivery, bringing ideas together from a variety of sources to help advance clinical research with common goals that are patient-focused.

They currently offer conferences for pharma/biotech professionals including R&D leaders, CEOs, business development/licensing, medical affairs/safety, chief patient officers/advocates, clinical innovation champions, investors and drug delivery specialists. The company also publishes six newsletters and produces PharmaTalkRadio and virtual events.

SOURCE: EuropaWire

Biotech, Consultations, Disorders, Healthcare, Healthcare Information, Healthcare Professionals, Healthcare Services, Healthcare Solutions, Psychiatry, Public Health, Society

European public-private project to advance precision psychiatry by introducing biology into clinical routine

Leave a comment

PARIS AND MONTPELLIER, 30-Mar-2022 — /EPR HEALTHCARE NEWS/ — ALCEDIAG announces the launch of the EDIT-B Consortium, supported by the European Institute of Innovation and Technology for Health (EIT Health). This newly formed European public-private partnership aims at advancing precision psychiatry by introducing biology into clinical routine.

Around 300M people in the world are affected by depression. Studies show that up to 40% of them may be misdiagnosed and potentially bipolar. As a result, diagnosis is often delayed by an average of 7.5 years, worsening patients’ mental and physical conditions as well as their loved ones’ quality of life.

The EDIT-B Consortium aims to solve this diagnostic challenge by using specific RNA editing based biomarkers and artificial intelligence to validate and commercialize an accurate, reliable, and quick blood test to diagnose bipolar disorder.

The Consortium brings together prominent members from across Europe who will be working over the next three years to achieve this goal: Alcediag, Alcen, Capital Region of Denmark, Fundació Clinic per la Recerca Biomèdica, Fundació Sant Joan de Déu, GHU Paris Psychiatrie & Neurosciences, Hospital Clínic de Barcelona, Parc Sanitari Sant Joan de Déu, ProductLife Group and Synlab. With a total budget of € 5.2 million, EDIT-B is co-funded by the EIT Health (€ 2.5M) and the partners.

“This project will accurately separate bipolar disorder from unipolar disorder. This distinction is extremely important clinically, because the treatments are different. EDIT-B Consortium gathers all relevant expertise and as the principal investigator in the clinical trial, I hope we will be able to validate a test that will improve the lives of many people living with bipolar disorder”, says Prof. Eduard Vieta from the Hospital Clínic de Barcelona.

SYNLAB is the first diagnostic service provider in Europe, present in 36 countries in 4 continents and committed to developing high value solutions for patients  focusing on medical excellence and customer centricity.

Maurizio Ferrari, SYNLAB Italy Chief Medical Officer says: “innovation in healthcare is a key pillar for the customer centricity and  we are very proud to be part of this European research project that really may help patients with psychiatric disorders”.

“I am proud to see that the EDIT-B consortium led by our partner Alcediag – a subsidiary of Alcen – will tackle the challenge of improving the diagnosis of bipolar disorder. In doing so, they support EIT Health main mission which is to help citizens live healthier and longer lives and at the same time put the spotlight on mental health which is key to the proper care management and wellbeing of our communities”, adds Jean Marc Bourez, interim CEO of EIT Health.

“On this World Bipolar Day, Alcediag team is happy to announce its contribution to solving the bipolar disorder diagnostic issue.  We are proud and grateful to our partners and the EIT Health for this opportunity to advance science while having a positive impact on people’s lives”, said Alexandra Prieux, CEO of Alcediag.

SOURCE: EuropaWire

Biotech, Diagnostics, Disorders, Healthcare, Healthcare Information, Pharmaceuticals, Psychiatry, Psychologist, Public Health, Society

Kenneth Research: Increasing Concern for Mental Health Disorders to Drive Market Growth for Mental Health Software and Devices

Leave a comment

NEW YORK, 21-Mar-2022 — /EPR HEALTHCARE NEWS/ — Every year, over 7 Million people are known to die by suicide, one of the major concerns of mental health, according to the statistics by the World Health Organization (WHO). Calculatedly, this comes to one person every 40 seconds. Moreover, in the year 2019, suicide accounted for 1.3% of the total number of deaths around the globe. On the other hand, mental health disorders, such as depression, affected 3.8% of the global population, or around 280 Million people. This included 5.0% adults and 5.7% aged adults above 60 years of age.

Kenneth Research recently released a report titled “Global Mental Health Software and Devices Market” which includes a detailed analysis of the market dynamics along with the impact of COVID-19 on the market growth during the forecast period, i.e., 2021-2030. The report also includes the regulatory and standard landscape, and in-depth research about the market growth across the five major regions, i.e., North America, Europe, Asia Pacific, Latin America, and the Middle East & Africa.

In Europe, Austria (24 males, 5.6 females), Belgium (23 males, 8.6 females), France (22 males, 5.9 females), Finland (22.9 males, 7.6 females), Germany (17.3 males, 4.8 females), Sweden (17.7 males, 7.0 females), Netherlands (15.7 males, 7.0 females), has shown the highest number of death rates and self-harms per 100,000 inhabitants.

As COVID19 sweeps the global economies, Europe is one of the worst hit since 2020. As new COVID guidelines, lockdown and restriction comes into force, economies have reported elevated cases of anxiety and stress. Especially quarantine and its ill impacts have pushed levels of loneliness, depression, drug use, alcohol consumption, suicidal behavior and self-harm are pushed to another level.

Request for Research Report Sample- https://www.kennethresearch.com/report-details/mental-health-software-and-devices-market/10352350

Mental health is a major concern globally and with the rising prevalence of different types of such disorders in recent years, as well as with the growing awareness for these diseases by governmental bodies, the disease has been included in the list of 17 Sustainable Development Goals (SDGs) of the United Nations. Moreover, the situation for the disease has also gained massive focus, especially to treat the elderly population. This can be attributed primarily to the increasing elderly population count over the past few years, and the growing awareness for mental health and well-being amongst these age groups. In the other statistics by the WHO, the proportion of the population of age 60 years and over around the world is expected to double from 12% to 22% between 2015 and 2050. The statistics further stated that over 20% of these adults suffered from a mental or neurological disorder, and 6.6% of all disabilities amongst these population groups accounted for such disorders. Additionally, around 5% and 7% of these populations had been affected with dementia and depression respectively, which are the two most common mental and neurological disorders.

The global mental health software and devices market generated a revenue of USD 3883.94 Million in the year 2020 and is further expected to grow with a CAGR of 13.28% during the forecast period and touch a value of USD 13367.12 Million by the end of 2030. The growth of the market can primarily be attributed to the growing need for advanced patient monitoring and patient management applications amongst healthcare service providers for those treating mental disorders, backed by the surge in the number of mental health patients worldwide. Besides this, the increasing number of these patients is expected to drive the need for advanced devices which can help for early diagnosis and treatment, therefore contributing to the market growth in the coming years. For instance, the prevalence of dementia, which is known for deteriorating the memory, thinking, behavior, and the ability of the patients to perform everyday activities, is expected to increase to 82 Million by 2030, and further touch 152 Million by 2050, according to the statistics by the WHO. On the other hand, according to the statistics by United Nations Children’s Fund (UNICEF), in the year 2019, between the ages 10 and 14, 34,840,000 female adolescents and 44,647,000 male adolescents suffered from mental disorders. Moreover, between the ages 15 and 19, 41,712,000 female adolescents and 44,563,000 male adolescents had suffered from the same disorder. The surge in these cases is expected to boost the demand for diagnostic devices for the treatment of the disorder, and in turn, drive the market growth.

Request for Research Report Sample- https://www.kennethresearch.com/report-details/mental-health-software-and-devices-market/10352350

The growth of the global mental health software and devices market can also be attributed to the increasing number of government initiatives that focus on maintaining good mental health and well-being of the individuals of nations worldwide. For instance, in May 2013, during the 66th World Health Assembly, the Comprehensive Mental Health Action Plan 2013-2020 developed by the WHO was adopted by the Ministers of Health of the 194 Member States. This action plan was further extended until 2030 in the year 2019, during the 72nd World Health Assembly. On the other hand, according to the statistical report titled “Mental Health Atlas 2020”, published by the WHO, 75% of the Member States had a stand-alone policy or plan for mental health. This was an increase from 68% in the year 2014.

Additionally, the statistics also stated that 57% of the Member States had a stand-alone mental health law. This was an increase from 51% in the year 2014. Besides this, since 2017, 46% of the WHO Member States had updated their health policy or plan, while 27% of them had updated their law regarding mental health.

The global mental health software and devices market is segmented on the basis of region into North America, Europe, Asia Pacific, Latin America, and the Middle East & Africa. Out of the market in these regions, the market in North America generated the largest revenue of USD 1557.47 Million in the year 2020 and is further expected to touch USD 5382.17 Million by the end of 2030. One of the major factors anticipated to drive the growth of the market in the region is the increasing awareness for mental health and the rising need amongst healthcare service providers to improve their services to patients who are suffering from the disease. For instance, according to the statistics by the National Alliance on Mental Illness (NAMI), in the United States, in the year 2020, 1 in 5 U.S. adults experiences a mental illness, while 1 in 20 experienced a serious one, and 1 in 15 experienced both a substance use disorder and mental illness. In addition to this, 26.3 Million adults in the nation received virtual mental health services during the COVID-19 pandemic. Amongst those who received these services, 17.7 Million people experienced delays or cancellations in appointments, while 7.3 Million experienced delays in getting prescriptions. Moreover, 4.9 Million people were unable to access needed care. The market in the region is segmented by country into the United States and Canada. Out of the market in these countries, the market in the United States is expected to hold the largest revenue by the end of 2030 and also grow with the highest CAGR of 13.36% during the forecast period.

Request for Research Report Sample- https://www.kennethresearch.com/sample-request-10352350

On the other hand, the mental health software and devices market in Europe generated a revenue of USD 1265.71 Million in the year 2020 and is further expected to touch USD 4360.54 Million by the end of 2030, by growing with a CAGR of 13.31% during the forecast period. One of the major factors anticipated to drive the growth of the market in the region is the growing reforms in the diagnosis of mental health. For instance, on the 13th of May, 2019, the Parliamentary Assembly of the Council of Europe (PACE) on Social Affairs, Health, and Sustainable Development, had urged the member States of the Council of Europe to end coercive practices in mental health settings and further adopt a human rights-based approach which is respectful of medical ethics. The market growth in the region can also be attributed to the increasing government initiatives to improve behavioral health services and the surge in the adoption of electronic health records (EHR). The market in the region is further segmented by country into Germany, France, United Kingdom, Italy, Spain, Russia, Netherlands, and the Rest of Europe. Amongst the market in these countries, the market in France is expected to generate the largest revenue of USD 988.54 Million by the end of 2030 and further grow with a CAGR of 13.75% during the forecast period. Additionally, the market in the nation generated a revenue of USD 275.93 Million in the year 2020. Furthermore, the market in Germany registered the second-largest revenue of USD 249.35 Million in the year 2020 and is further expected to touch USD 911.35 Million by the end of 2030.

The study further incorporates Y-O-Y Growth, demand & supply and forecast future opportunity in North America (U.S., Canada), Europe (U.K., Germany, France, Italy, Spain, Hungary, Belgium, Netherlands & Luxembourg, NORDIC [Finland, Sweden, Norway, Denmark], Poland, Turkey, Russia, Rest of Europe), Latin America (Brazil, Mexico, Argentina, Rest of Latin America), Asia-Pacific (China, India, Japan, South Korea, Indonesia, Singapore, Malaysia, Australia, New Zealand, Rest of Asia-Pacific), Middle East and Africa (Israel, GCC [Saudi Arabia, UAE, Bahrain, Kuwait, Qatar, Oman], North Africa, South Africa, Rest of Middle East and Africa).

The global mental health software and devices market is segmented by delivery model into subscription model and ownership model. Amongst these segments, the subscription model segment is projected to garner the largest revenue of USD 2442.34 Million by the end of 2022. Further, the segment is also expected to grow with the highest CAGR of 11.82% during the forecast period. In North America, the segment is expected to garner the highest market share by the end of 2030, while in Europe, the segment is projected to garner the largest revenue of USD 762.37 Million by the end of 2022.

The global mental health software and devices market is further segmented by end user into community clinics, hospitals, private practices, and home care settings. Among these segments, the community clinics segment registered the largest revenue of USD 1644.62 Million in the year 2020 and is further expected to touch a revenue of USD 5667.35 Million by the end of 2030. In North America, the segment generated the largest revenue of USD 660.52 Million in the year 2020 and is further projected to reach USD 2285.27 Million by the end of 2030, by growing with a CAGR of 13.35% during the forecast period. On the other hand, in the Asia Pacific, the segment is anticipated to garner the largest revenue of USD 1124.71 Million by the end of 2030, up from a revenue of USD 317.70 Million in the year 2020. Moreover, in Japan, the segment is expected to garner the largest revenue of USD 244.73 Million and further grow with a CAGR of 14.34% during the forecast period.

The global mental health software and devices market is also segmented on the basis of component, functionality, and mode of access.

Global Mental Health Software and Devices Market, Segmentation by Component

  • Software
    o Integrated Software
    o Standalone Software
  • Devices

Global Mental Health Software and Devices Market, Segmentation by Functionality

  • Clinical Functionality
    o Electronic Health Records (EHR)
    o Clinical Decision Support (CDS)
    o Care Plans/Health Management
    o E-Prescribing
    o Telehealth
  • Administrative Functionality
    o Patient/Client Scheduling
    o Document/Image Management
    o Case Management
    o Workforce Management
    o Business Intelligence
  • Financial Functionality
    o Revenue Cycle Management
    o Managed Care
    o Accounts Payable/General Ledger

Global Mental Health Software and Devices Market, Segmentation by Mode of Access

  • Desktops/Laptops
  • Tablets/Smartphone

Some of the prominent industry leaders in the global mental health software and devices market that are included in our report are Cerner Corporation, Netsmart Technologies, Inc., Qualifacts Systems, Inc., Valant, NXGN Management, LLC, Core Solutions, Inc., Holmusk USA, Inc., The Echo Group, Welligent, Inc., Credible Behavioral Health, Inc., IBM, and others.

Request for Research Report Sample- https://www.kennethresearch.com/sample-request-10352350

 

SOURCE: EuropaWire

Alternative medicine, Diseases, Disorders, Gynecology, Health Products, Healthcare, Healthcare Products, Medicine, Reproductive Medicine

When Suffering From Endometriosis, The Natural Therapy Fuyan Pill Is A Useful Medicine For Pregnancy Plan Of Female Patients

Leave a comment

Los Angeles, California, U.S.A., 2021-Jan-14 — /EPR HEALTHCARE NEWS/ — Reuters recently reported that British lawmakers called for urgent government action to support 1.5 million females with endometriosis — a debilitating condition that leads to absenteeism from school and work and can cause infertility. Female health experts said the lack of funding for research into the crippling illness — which affects one in ten females worldwide — showed how female health issues were often marginalized.

Female health issues should be paid attention to, while endometriosis is very harmful to the body health in females, which can cause persistent dysmenorrhea, menstrual disorders, urinary pain, low back pain, pelvic bleeding and other problems. If things go on like this, endometriosis will affect their learning efficiency, working performance, social life, relationships and mental health. In addition, they may have to face the problem of infertility.

In general, due to the ectopic endometrium attached to the abdominal cavity or ovarian surface, it can cause periodic shedding, congestion, edema, thus leading to the formation of chocolate cysts on the ovarian surface. The abnormal tissues can affect ovulation and then lead to infertility. Furthermore, the ectopic endometrium in the abdominal cavity will cause the viscera to stick together, causing the fallopian tubes to be blocked. In this case, the sperm and the egg cannot be combined into a fertilized egg in the fallopian tube, resulting in female infertility.

If a female friend has endometriosis and suffers from long-term infertility, doctors generally recommend her to receive a surgery to excise the diseased tissues. However, in some cases, due to the serious adhesions of the lesions, doctors are often unable to make a complete elimination, thus leading to a high recurrence rate of endometriosis.

On the flip side, doctors may adopt the therapeutic surgery, which involves the complete removal of both ovaries and the uterus. Actually, it’s relatively cruel to young and childless females, which not only directly deprives them of the reproductive rights, but also potentially triggers postmenopausal syndrome. Surgery can also induce secondary infections, leading to other inflammations such as pelvic inflammatory disease.

Obviously, surgery is a double-edged sword, which surely has some positive effects, but is not the best option, especially for females who want to raise children. A sound body is essential for a successful pregnancy. If you have to suffer from extra pain and risks due to the treatment method, it’s actually not worth trying. As a result, more and more patients with endometriosis are looking for safer solutions, and the natural therapy Fuyan Pill is a useful medicine for them.

The herbal medicine Fuyan Pill is developed by Wuhan Dr.Lee’s TCM Clinic, which has been granted the national patent in China. It can eliminate inflammations, kill various bacteria and viruses, clear away heat, remove blood stasis, relieve pain and so on. It’s made from more than 50 selected herbal ingredients, including radix bupleuri, poria, scutellaria baicalensis, gardenia, Chinese yam, talc, angelica sinensis, peach seed, safflower, licorice, etc.

The Fuyan Pill can effectively relieve the pain and discomfort caused by endometriosis, unblock the fallopian tubes, solve the adhesion issues, and provide a sound physiological environment for fertilization. In terms of traditional Chinese medicine, the cause of endometriosis is qi stagnation and blood stasis, and Fuyan Pill features the ability to promote blood circulation, remove blood stasis, eliminate inflammation and abnormal tissues. It can also regulate the menstruation and hormones, enhance the body immunity, and improve the female self-healing capacity.

As a natural therapy, Fuyan Pill has a strict formula and ratio in terms of the composition. Based on Dr. Lee’s more than 30 years of clinical experience, Fuyan Pill has been proved as an effective and safe oral product, which won’t lead to toxic side effects or unnecessary physiological pain and discomfort. For females who aspire to be a mother, Fuyan Pill can help them overcome endometriosis and get pregnant naturally.

We once cured a patient with endometriosis. Emily, a 28-year-old married female in America, was diagnosed with endometriosis and blocked fallopian tubes in 2017. After several attempts at treatment methods, including laparoscopic surgery and hormone therapy, her problems remained unresolved. Introduced by a friend last year, she contacted us and expressed her strong desire for childbirth through email, so we suggested her taking the Fuyan Pill.

After a month of treatment, Emily said that those painful symptoms had been improved so much that she didn’t hesitate to continue taking the pill for several months. Her illness has improved greatly and she is happy to tell us that she got pregnant two months ago. Now, she is actively preparing for the arrival of her baby.

As a natural plant medicine product, Fuyan Pill has a broad-spectrum bactericidal action with no side effects, which can not only treat endometriosis but also react well on pelvic inflammatory disease, endometritis, salpingitis, chlamydia infection, pelvic abscess, and other related problems. As a result, it can help females solve infertility caused by these gynecological diseases. We hope that females pay more attention to their body health. If you suffer from some problems mentioned above, Fuyan Pill is worth trying.

For more information about Fuyan Pill, please visits: https://global.fuyanpills.com/

About Dr. Lee Xiaoping:
Dr. Lee Xiaoping graduated from Hubei College of Traditional Chinese Medicine, China. She qualified as a herbalist 40 years ago and is a highly experienced medical professional. She specializes in the field of male and female reproductive and urinary system diseases. She has devoted 30 years to her clinic and worked on the formula of Fuyan Pill for years. The medicine has proven to be effective and cured thousands of people who suffered from endometriosis as well as its complications.

Media contact:

Lee Xiaoping
Herbalist
Wuhan Dr.Lee’s TCM Clinic
+86- 027-87105085
wuhandrli@gmail.com
herbalistlee@yahoo.com
wuhandrlee@hotmail.com

Via EPR Network
More Healthcare press releases

Biotech, Child health, Diseases, Disorders, Doctors, Health Products, Healthcare, Healthcare Information, Healthcare Products, Healthcare Professionals, Healthcare Services, Healthcare Solutions, Pediatrics, Pharmaceuticals, Physicians, Society, Urology

Palette Life Sciences unveils 4 international sites for its Deflux online presence

Leave a comment

SANTA BARBARA, CALIF. / STOCKHOLM, 27-Oct-2020 — /EPR HEALTHCARE NEWS/ — Palette Life Sciences, a fully integrated global life sciences company dedicated to improving patient outcomes, today introduced valuable new online resources for healthcare providers in France, Germany, Italy and Spain. By expanding its Deflux online presence to international audiences, Palette Life Sciences demonstrates its commitment to supporting the global paediatric community.

Deflux.fr is a French-language resource for healthcare providers in France. Deflux.com/de is a German-language site serving practitioners in Germany. Deflux.com/es and Deflux.it are English-language sites serving physicians in Spain and Italy respectively. These new sites offer best-in-class online resources, important information and education about VUR, including symptoms, causes, risk factors and treatment options, such as Deflux®. All of the European sites provide physicians with access to the global Deflux Learning Center, a leading education platform that features information and training for paediatric urologists and their peers who treat VUR. The Deflux Learning Center includes clinical articles, educational videos, webinars, brochures, downloadable tools and The PedSpace podcast series, created for and presented by paediatric urology healthcare professionals.

The Deflux Learning Center for each respective country also provides downloadable educational materials for parents and caregivers managing children with vesicoureteral reflux (VUR).

“My personal long-term experience with Deflux has proven its effectiveness and safety in reducing VUR and preventing UTI recurrence in patients who fail medical management, thus avoiding use of long-term antibiotics. It is my hope that the new website initiative, which includes helpful resources for physicians, will help raise awareness of this treatment option in patients with primary VUR, troubled by recurrent febrile UTIs,” said Dr. Marie-Klaire Farrugia, Consultant Paediatric Urologist and Service Lead for Paediatric Surgery at Chelsea & Westminster and Imperial College Hospitals.

“We are excited to offer these new online resources to the healthcare community in France, Germany, Italy and Spain,” said Rich Low, Head of Marketing at Palette Life Sciences. “We are confident they will benefit the global paediatric urology ecosystem and serve as valuable resources by providing critical information and access to educational resources through the Deflux Learning Center.”

SOURCE: EuropaWire

Addictions, Disorders, Healthcare, Healthcare Information, Healthcare Professionals, Healthcare Services, Rehab, Society

Exclusive Interview on Addictiveness During the Coronavirus Pandemic with Dr. Henry Balzani, the “Addictiveness Doctor”

Leave a comment

Fort Lee, NJ, USA, 2020-May-15 — /EPR HEALTHCARE NEWS/ — In an exclusive interview with Practicomm, nationally recognized addictiveness expert provides valuable update on controversial addiction issues.

Q1. In light of the Coronavirus pandemic, it appears that people who were not addicts could become addictive just from being quarantined? Do you think that would be a large number of new addicts?

Our “Basic Survival Thinking” is mostly negative and being quarantined produces increased life stresses such as, unemployment, financial loss, fear of death, forced isolation and mental illnesses. During the pandemic, there has been an increase in alcohol consumption (as well as other substances) to blunt the negative thoughts. Also, there was an increase in sugary-high carb “comfort foods” used to stimulate positive feelings through the increased production of neurotransmitters like dopamine and serotonin.

But in fact, almost all the Covid-19 deaths are directly related to our addictiveness to high carb, processed food and the abuse of drugs, alcohol, tobacco, especially high blood sugar, diabetes and high blood pressure, which compromise the immune system. In brief, “Yes”, there will be an increase in addictiveness to try to relieve the pressure and mental stress from this pandemic

Q2. Some people say that smoking is a worse addiction than alcohol and drugs. Is that true? If so, why?

Smoking leads to strong persistent cravings for more nicotine within minutes to hours of the last puff. Vaping allows nicotine to almost always “be in hand’ day and night, inside or out. Addiction to different substances varies with the substance and the individual, and is tempered by availability, legality, cost, social acceptance, the onset of health issues, age of user, and more. Smoking health issues usually develop later in life; products are readily available, and vaping is now cool and socially acceptable. Fortunately, tobacco products are banned in buildings and outside in parks, thus making it harder to use freely.

Q3. It seems that most addiction treatment centers have a high percentage of patients who are “cured” for only a small period of time before going back to the addiction. Is that a correct statement?

The LIFETIME tendency to relapse (recidivism) after treatment is still high. The “Post Treatment Cure” is, for most, a physiologic removal of the substance from the body; and, for a time, a psychologic re-education and respite for the client before entering the real world. The “Roots of Addiction” can start early in life and become deeply and unconsciously embedded over years, and can always be reactivated under stress. To achieve a lifetime cure, addicts must always be actively involved in their recovery, because life just doesn’t get easier. I have seen my clients relapse a number of times before being able to maintain sobriety; and, some who have relapsed after many years of sobriety.

Q4. Can addicts actually change the way they think? How would they do that if they could? Does this vary by the type of addiction?

Adult addicts can change the way they think if they have a strong Desire, Interest and Commitment to recover. But, being pushed into recovery usually doesn’t last long.

They must deal with the root causes of their addiction, as they can be reactivated during times of stress. For any addiction, they must fully commit and actively participate in their process of Detox, Treatment, Counseling, and follow up, remove people places and things, and have (or seek out) a strong support system which can help in stressful situations. The stresses of life will always be there and it’s the psychological aspect of addiction that can be persistent!

For more information on the root causes of addiction, visit  addictivenessdoctor.com and/or go to Dr.Balzani on Facebook.

Via EPR Network
More Healthcare press releases

Alternative medicine, Disorders, Healthcare, Healthcare Products, Healthcare Services, Healthcare Solutions, Non-Surgical Procedure, Therapies, Urology

Study published in World Journal of Urology confirms Fotona SMOOTH® laser technology is a safe, effective & minimally-invasive solution for stress and mixed urinary incontinence

Leave a comment

LJUBLJANA, Slovenia, 21-Sep-2018 — /EPR HEALTHCARE NEWS/ — The latest study published in the World Journal of Urology (Comparison between erbium‑doped yttrium aluminum garnet laser therapy and sling procedures in the treatment of stress and mixed urinary incontinence – https://doi.org/10.1007/s00345-018-2445-x) provides further confirmation that Fotona SMOOTH® laser technology is a safe, effective and minimally-invasive solution for stress and mixed urinary incontinence (SUI and MUI). The article, written by Dr. Nobuo Okui, compares Fotona’s minimally invasive IncontiLase® Er:YAG laser therapy with the more conventional TVT and TOT surgical sling procedures.

Asian Study Confirms Favorable Results of Fotona SMOOTH® Laser Therapy for Urinary Incontinence

In the study performed by Dr. Okui, 50 Japanese women were treated either surgically (tension-free vaginal tape – TVT or transobturator tape – TOT) or with a Fotona laser. The 1-h pad test, ICIQ-SF, and overactive bladder-symptom score were used to assess the patients before and 12 months after treatment. Laser therapy was performed by first applying a local anesthetic to the vaginal wall and then inserting a probe into the vagina. Laser irradiation was performed for 20 min with an Er:YAG wavelength of 2940 nm (Dynamis XS, Fotona) for a total of three treatments (alternating every month). Results of the 1-h pad test and ICIQ-SF showed comparable improvements in SUI in the sling and laser therapy groups, while some of the patients with MUI in the TVT and TOT groups showed exacerbation. In conclusion, the TVT and TOT procedures and the laser therapy are comparable for SUI; however, laser therapy is superior in terms of MUI and complications. The study thus once again confirms the safety and efficacy of Fotona SMOOTH® laser therapy for urinary incontinence.

Urinary Incontinence Treatment Options

Conventional treatment options for urinary incontinence are surgical, and include TVT or TOT sling procedures, which involve inserting a synthetic material. Problems often arise with artificial meshes that require new treatment methods. With the Fotona SMOOTH® Er:YAG laser thermotherapy (also known as IncontiLase®), the goal is to provide a minimally invasive therapy based on vaginal collagen hyperthermia followed by collagen remodeling and new collagen synthesis, which results in overall regeneration of aged or stressed vaginal tissues and subsequently greater support to the bladder.

Unique Fotona SMOOTH® Technology for Maximum Safety

Patient safety is the primary concern and, for this reason, the patented Fotona SMOOTH® technology holds a very unique position within the spectrum of gynecological treatment options. It is a non-surgical procedure (no incisions) and without implants or appliances. The Fotona SMOOTH® method of dual-tissue regeneration is completely non-ablative and therefore minimally invasive to the vaginal wall. The treatment involves an additional superficial heat-shocking mechanism of tissue regeneration, and a unique self-regulating safety feature. These dual-tissue regeneration characteristics of the Fotona SMOOTH® Er:YAG laser allow for an exceptionally high degree of safety and efficacy in thermotherapy of the vaginal wall. This is what makes Fotona SMOOTH® a significantly safer alternative to many widely used and more-invasive procedures.

Evidence-Based Laser Medicine

Over the past few years numerous (over 35) other studies on Fotona SMOOTH® laser therapy have been published by distinguished gynecologists from around the globe in some of the most trusted and renowned international scientific journals, all with favorable results (https://www.laserandhealthacademy.com/en/practitioners/recommended-reading/gynecology/). One such noteworthy clinical paper published in March 2018 by Dr. Adolf Lukanovic and Dr. Mija Blaganje is the first randomized controlled trial study (on 114 premenopausal parous women) to evaluate the efficacy and safety of non-ablative Er:YAG laser therapy as an alternative non-invasive treatment of SUI and the improvement of sexual gratification (published in the European Journal of Obstetrics & Gynecology and Reproductive Biology. 2018 (224): 153-158). The results from this study indicate that a single session of IncontiLase® treatment improves the impact of SUI symptoms on quality of life and sexual function in premenopausal parous women significantly better than placebo.

In another Asian study, Dr. Yi-Wen Tien et al. from the Chang-Hua Hospital in Taiwan examined the effects of laser treatment for female SUI on pad weight, urodynamics, and sexual function in 35 women (published in the International Urogynecology Journal. 2017; 28(3): 469-476). The study reveals that the effect of IncontiLase® treatment for mild SUI was moderate at the 6-month follow-up. Moreover, it improved LUTS, quality of life, and the sexual function of both partners. The authors conclude that the IntimaLase® procedure is very effective in the treatment of SUI and is not associated with any severe adverse effects.

Similarly, Dr. Yi-Hao Lin et al. from the Chang Gung Memorial Hospital in Taiwan obtained favorable results. Their study investigated the effects of non-ablative laser treatment on overactive bladder (OAB) syndromes, SUI and sexual function in 30 women with urodynamic stress incontinence (published in the Taiwanese Journal of Obstetrics & Gynecology. 2017 (56): 815-820). The results showed that IncontiLase® treatment can resolve SUI and coexistent OAB symptoms three months after therapy, while repeated laser therapy may be necessary after six months. The results also revealed that sexual gratification improved, while no major adverse effects were noticed.

The quantity and quality of the studies performed with Fotona SMOOTH® laser therapy is such that Fotona’s Dynamis has been cleared in the European Union for SUI (IncontiLase®), vaginal laxity – vaginal relaxation syndrome (IntimaLase®), genitourinary syndrome of menopause – GSM (RenovaLase®) and pelvic organ prolapse (ProlapLase®), giving women the option to choose a safer and less-invasive treatment alternative. In Asia, the Taiwan Food and Drug Administration has already cleared Fotona Dynamis for mild to moderate SUI, and the Singapore Health Sciences Authority has cleared the Dynamis for the treatment of SUI and GSM.

SOURCE: EuropaWire

Alternative medicine, Diseases, Disorders, Doctors, Healthcare, Healthcare Services, Neurology, Non-Surgical Procedure, Therapies

TESTmyBRAIN opens its first center of Functional Neurology in Europe

Leave a comment

GENEVA, 2016-Jun-8 — /EPR Healthcare News/ — TESTmyBRAIN (Switzerland) has opened its first center of Functional Neurology in Europe. This non-invasive therapy (no medication, no surgery) coming from the United States helps patients suffering from migraines, concussions, strokes, AD/HD, Parkinson disease, Alzheimer, … all disorders related to the brain and the central nervous system.

This innovative therapy combines several approaches and relies mainly over 3 decades of research on the eye-movements to diagnose and treat. Completely adopted and established in the United States, this therapy is almost unknown in Europe.

This is the reason why TESTmyBRAIN Switzerland is happy to bring the American experts to Europe to teach other doctors and to help patients differently with their pain.

SOURCE: EuropaWire

Addictions, Clinics, Consultations, Diagnostics, Disorders, Healthcare, Healthcare Professionals, Healthcare Services, Psychiatry, Psychologist, Society

Private Addiction Treatment in London Now Offered by a Pilot Scheme from South London and The Maudsley NHS Foundation Trusts

Leave a comment

The Addictions Clinical Academic Group at South London and The Maudsley NHS Foundation Trust today announced a new pilot scheme offering private addiction treatment in London from their team of experts.

Nationally recognised as some of the UK’s leading addiction experts and part of the National Addiction Centre, the Maudsley team currently provide expert advice to a number of professional bodies including the GMC, the CAA, and National Air Traffic Control amongst others.

The new scheme will utilise some of their specialist addiction Consultants who will work with the private provider Clinical Partners to offer treatment to private patients in central London.

The new service will accept self-referring patients as well as referred privately funded patients from both NHS and Private Doctors and referrals from private companies. Clients are seen by the Maudsley clinicians at the Clinical Partners Wimpole Street and City consulting rooms. This is the first time that many of these distinguished clinicians have been available for patients to see privately.

The new outpatient services allow patients to continue to work while receiving the treatment they need, as well as referring those needing inpatient care to a choice of NHS and private providers. The team of Consultant Psychiatrists, Psychologists and Therapists are able to help with a wide range of addictions including alcohol, drugs, prescription medication, party drugs and sex, spending or gambling.

Mark Allen, Service Director at the Addictions Clinical Academic Group said “We’re delighted to bring some of SLAM’s expertise to this innovative new partnership between the private and public sectors.”

Barny Guthrie, CEO of Clinical Partners, said “Clinical Partners is very happy to be able to offer our clients access to some of the UK’s top addiction specialists. The Maudsley Hospital is host to a huge amount of talent and expertise and we are extremely pleased that SLAM has chosen to work with Clinical Partners.”

For further information about private addiction treatment in London or to arrange an appointment please visit http://www.clinical-partners.co.uk/how-can-we-help-you/addictions-clinic/partnership-with-maudsley-hospital

Via EPR Network
More Healthcare press releases

Alternative medicine, Diseases, Disorders, Fitness, Healthcare, Healthcare Solutions, Online, Society

Holistic Health Breakthrough Can End Sickness Now

Leave a comment

Holistic health and wellness expert Steve Carney has relaunched his health website, EndSicknessNow.com. The newly revamped site has also reached a milestone with its 75th article. The site’s mission is to help readers and clients reach optimum health and longevity, a mission inspired by Steve’s own battles with serious health and life obstacles.

“After a terrible childhood illness, I spent 20 years researching health, nutrition and disease prevention and treatment. I use a unique blend of consulting, support and encouragement to help each client achieve their health goals. Common health problems, such as high blood pressure, high cholesterol, excess weight, pain and inflammation often improve in a few weeks. Client’s enjoy more energy, stamina, and better sleep,” Steve explained.

End Sickness Now is an expert source for optimum health and disease prevention. Steve provides the latest research and newest breakthrough methods for easy weight loss, preventing and treating health conditions, and improving mood. The site also helps to expose numerous nutrition, health and disease myths perpetrated by the medical industry and the media.

“The constant flow of myths and misinformation creates confusion. Decades of nutrition and medical myths have harmed people’s health, along with their chances to live a longer life,” Carney stated.

Steve is a Certified Nutrition and Fitness expert, and Professional Life Coach. For those who wish to take their first steps toward optimum health and wellness, contact Steve for more information about a free, 30-minute phone assessment.

Via EPR Network
More Healthcare press releases

Alternative medicine, Disorders, Health Products, Healthcare Information, Healthcare Solutions, Online, Society, Sports Medicine, Therapies

Professional Tennis Player Overcomes Debilitating Anxiety & Panic Disorder Unconventionally

Leave a comment

The tennis world has seen many comebacks in the past but none as unlikely as this one. After 6 years Dennis Simsek a professional tennis player and teaching pro on the ATP tour has naturally been able to overcome Generalized Anxiety Disorder and Panic Disorder, after being moments from taking his own life. Emergency visits before and after important tennis matches, intense physical sensations that resembled serious illnesses during matches, and overwhelming fearful thoughts were just a few of the personal mental and physical battles.

The ‘Me vs Myself On & Off The Court’ eBook outlines natural and unconventional ways Dennis overcame his mental illnesses. The coping strategies such as anti anxiety pills were only a short term fix that didn’t lead to long term recovery, and this is causing a major roadblock for people suffering from intense panic and anxiety these days. The ups and downs of this inspirational story will give readers a glimpse into the life of a professional athlete that feared everything from crowded areas to up tempo music. Readers will be able to relate to these stories, gain strength to stay motivated to face their fears, and reach their dreams through my online blogs and 30 day fear eliminator challenge set to launch on Jan 1st.

This eBook as well as the many interactive tools were launched through The Anxious Athlete website on Dec 15th, and can be purchased through the website below. I am hoping you will be able to see the enourmous benefits that athletes and non athletes who suffer with mental illnesses will gain from reading this book.

Via EPR Network
More Healthcare press releases

Allergies, Business of Medicine, Child health, Disorders, Healthcare, Healthcare Information, Healthcare Products, Society

World Asthma Day 2012: San Francisco Childcare Centers Eliminate Exposure to Bleach Cleaning Products

Leave a comment

Bleach is a strong irritant, frequently linked to newly-acquired asthma. A recent decision by Compass Children’s Center in San Francisco to use exclusively “bleach-free” cleaning products resulted in visibly less asthmatic symptoms in both children and childcare workers.

According to the U.S. Department of Health – National Institutes of Health (NIH), asthma affects more than 25 million people in the United States and over 230 million people worldwide. As asthma typically begins in early childhood, the NIH is committed to reducing environmental risk factors in children in order to prevent asthma before it begins.

On the forefront of asthma prevention, the San Francisco Asthma Task Force in a 2011 report on Bleach Exposure in Child Care Settings , discovered a high correlation between bleach exposure and work-related new-onset asthma cases as well as the exacerbation of pre-existing asthma conditions. As a result they set about field-testing various sanitizers and initially recommended a number of bleach-free disinfectant and sanitizer alternatives.

Food Contact Sanitizer Recommended

In late April 2012 the task force issued an interim update to the 2011 report with the discovery of an accelerated hydrogen peroxide sanitizer, SaniDate Ready-to-Use (RTU) Hard Surface Sanitizer. This sanitizer can be used directly on food-contact surfaces and as a fruit & vegetable wash, requiring only 1 minute contact time to eliminate over 99.9% of bacteria and human health pathogens.

SaniDate RTU was also recently approved by San Francisco Department of Public Health and various city ministries have begun roll out of the product as it’s recommended bleach-alternative sanitizer for food-contact surface.

The following video features the story of Compass Children’s Center in San Francisco and the lives of children in poverty that are being affected for the positive by reducing and preventing asthma through their transition to a bleach-free environment.

SaniDate Ready-to-Use Hard Surface Sanitizer is available for retail or volume purchase through EnviroSelects LLC.

Via EPR Network
More Healthcare press releases

Biotech, Disorders, Doctors, Drugs, Genetics, Health 2.0, Healthcare, Healthcare Professionals, Hospitals, Pharmaceuticals, Therapies

Stem Cell Treatment Give CMT Patient Second Chance At Life!

Leave a comment

“Pat receive a life altering Stem Cell Treatment with the help of World Stem Cells, LLC. Pat went from couch bound to walking 1.5 miles on country dirt road, climbing stairs, gardening and playing piano all thanks to a stem cell treatment.”

Pat is a 69-year-old woman with Charcot-Marie-Tooth disease, or CMT. She had been experiencing the effects of CMT for more than thirty years, and her progressive motor sensory neuropathy had become severe enough to interfere with every aspect of her life. She could no longer play piano, balance well enough to climb up steps or get dressed easily or summon the energy to work for more than a couple of hours before taking a rest break. Pat’s form of CMT is CMT1A, which is the most common form of this autosomal dominant condition. Her symptoms were typical of CMT; patients typically endure progressive muscle wasting and weakness in the legs, and a later loss of hand strength, balance, coordination and fine motor skills.

Pat’s neurological disorder is hereditary, and the official position of the National Institute of Neurological Disorders and Stroke is that CMT has no cure. Decades ago, Pat had gone to a neurologist for electromyography, or EMG. The purpose of the procedure was to evaluate her muscle function, and it involved painful needles and days of muscle soreness after each session. Pat’s neurologist had refused to tell her the results because he said that she would “just give up” if she knew how bad they were. At this point, Pat’s symptoms were so crippling and unbearable that she contacted World Stem Cells, LLC worldstemcells.com to explore stem cell treatment as an option. She knew that the procedures were still being developed and experimental, and that they came with no guarantees. She remained interested in learning more and becoming educated on the options presented. At the time, she was unable to walk without a four-leg quad cane, and air and car travel were exhausting and caused unbearable pain. Pat has a long history of surgeries and was told that further surgeries would not assist her. She decided that she was not interested in any treatment that involved surgery with incisions, which is an aggressive approach and would demand recovery time. Stem cell therapy met her requirements of being minimally uncomfortable, requiring only hours for recovery and having a high level of safety, along with a good potential for changing her health quotient for the better.

Pat arrived in Cancun, Mexico, to the treatment site of World Stem Cells, LLC contract clinics, doctors, and hospitals. The first day, she met with physician Dr. Sylvia M. Abblitt to be evaluated, discuss her course of treatment and learn what to expect. She had been corresponding with Dr. Alan Kadish, the President of World Stem Cells, LLC. worldstemcells.com

Dr. Kadish is an unusual physician as he has training and practiced integrated primary care medicine combining conventional and naturopathic diagnostics and therapeutics for 27 years. He has been recognized as one of the leading quality physicians, in his field. Dr. Kadish is an American Board of Anti-Aging Medicine diplomat and completed numerous training programs in Achieving Clinical Excellence, or ACE, which provided opportunities to improve his practical skills in diagnosing and treating people based on their individual needs, using functional medical testing and treatment. He has been an advanced level practitioner (Autistic Research Institute) for autistic spectral disorder children and adults, since early 2000 and is certified in chelation therapy. As a naturopathic medical physician he lecturers frequently and is a host and guest on radio and internet outlets along with appearing in a number of print media publications. At World Stem Cells , LLC in addition to his management duties, he is a primary investigator engaged in research and designs of stem cell therapeutic protocols.

In Cancun, Pat met with specialists at Advanced Cellular Medicine Clinic. The clinic is headed by Dr. Sylvia Abblitt, who has the exclusive distinction of being among the few physicians who are licensed to perform autologous and allogeneic stem cell transplants in Mexico. Dr. Abblitt is a board-certified hematologist and oncologist. She has 11 years of expertise as a laboratory director and head of the hematology department at the Fernando Quiroz Hospital. She is a member of the American Association of Blood Banks and the International Cellular Medicine Society (ICMS).

The Cancun clinic that Pat visited is a contract clinic of World Stem Cells, LLC. It houses the state-of-the-art Advanced Cellular Engineering Lab. The high-tech lab is suited for providing patients with the most up to date stem cell treatments and for conducting stem cell research to improve future opportunities for health.

After her evaluation and discussion of treatment options, Pat decided to go ahead with the stem cell therapy. The procedure involved a needle puncture to harvest her bone marrow utilizing her own stem cells. Only a local anesthesia was necessary and though she described the procedure as “uncomfortable,” she added that it was“livable.” The procedure took less than half an hour, and she experienced no side effects.

Pat’s improvement was remarkable and rapid. In fact, she did not feel fatigued and overwhelmed with pain, as she had in the past, when she traveled back home from Cancun by airplane and car. Within days, she had regained her ability to play piano. Playing at church concerts had always been a passion of hers, but she had been unable to play before her stem cell treatment because of a lack of coordination. She had much more energy after treatment, and was able to garden, run errands and work, without feeling exhausted. Her sleep was more restful. Her husband and friends noticed that her agility and balance were better. She could climb up and down stairs more easily and walk around the house without clutching the walls. Her speed on the treadmill was increasing gradually and she now walks a mile and a half on country roads.

Pat is extremely grateful to World Stem Cells, LLC for changing her life and giving her hope. For the first time, she has reversed many of the negative changes that she had been experiencing for years due to her CMT and lack of effective treatment. Now, Pat and her husband are experiencing a bright future and thankful that Pat was given this second opportunity, following stem cell therapy.

Working under the guidelines set forth by international cellular medical society (ICMS) World Stem Cells, LLC provides Stem Cell Treatment for Ankylosing Spondylitis, Autism, Cerebral Palsy, Charcot-Marie-Tooth Disease (CMT), Crohn’s Diseases, COPD, Fuch’s disease, Guillain-Barre’ Syndrome, Hashimoto’s Thryroiditis, ITP, Kidney Diseases, Macular Degeneration, Lupus (SLE), Multiple Sclerosis, PAD, Parkinson’s disease, Rheumatoid Arthritis, Scleroderma, Stroke, Ulcerative Colitis at its contract Clinics, GLP laboratory, doctors and hospitals in the beautiful resort area of Cancun. We endeavor to provide the best care possible at a mediate price while providing documentation of all treatments that can be used to provide better future care and scientific data to the medical industry.

Via EPR Network
More Healthcare press releases

Business of Medicine, Disorders, Health Products, Healthcare, Healthcare Information, Healthcare Products, Healthcare Professionals, Healthcare Services, Healthcare Solutions, Online, Society

Helpful Information For People Who Suffer From Incontinence

Leave a comment

Incontinence can be described as the uncontrolled leakage of urine or faeces, and is an extremely common problem. But help is at hand. Incontinence UK is a leading UK supplier of incontinence products, incontinence pads and incontinence pants.

You’ll find a series of helpful frequently asked questions below, designed to help you gain a greater knowledge of the incontinence products available, so that when it comes to purchasing incontinence products, incontinence pads or incontinence pants of your own, you are able to make an informed decision.

Will one type of incontinence product suit all my needs?

This is not always the case, and different incontinence products, incontinence pads and incontinence pants will offer different benefits.

Some sufferers might prefer a smaller, thinner incontinence pad or incontinence pant during the day but a larger, more absorbent incontinence pad at night when their leakage could be more severe. Alternatively, some incontinence sufferers might prefer the simplicity of exchanging incontinence pads during their daily routine, but prefer the added security of incontinence pants on special occasions or long days out.

What are the benefits of disposable incontinence pads?

Disposable incontinence pads can be thrown away after usage, meaning that hygiene and convenience are great benefits. It is very easy to carry disposable incontinence products with you and change them as and when is needed. Incontinence UK supply a large range of disposable incontinence products, pads and pants; ensuring that you can find an incontinence product to suit your needs.

What are the benefits of washable incontinence products?

Over time, washable incontinence pants prove to be more economical and environmentally friendly than disposable incontinence products. With the look and feel of normal underwear, certain incontinence sufferers prefer to wear washable incontinence pants, and they can also be easier to store. It is important, however, to ensure that you have enough washable incontinence pants to suit your needs.

Via EPR Network
More Healthcare press releases

Biotech, Disorders, Doctors, Drugs, Genetics, Health 2.0, Healthcare, Healthcare Professionals, Hospitals, Pharmaceuticals

Great Ormond Street Hospital Supports Stem Cell Awareness Day

Leave a comment

Great Ormond Street Hospital and its research partner, The Institute of Child Health at University College London (UCL), are supporting Stem Cell Awareness Day, with UCL promoting the event with the launch of a new YouTube video featuring Mr Paolo de Coppi and his colleagues.

Mr. de Coppi is Clinical Senior Lecturer in the Surgery Unit at The Institute of Child Health at UCL and carries out stem cell research at Great Ormond Street Hospital. It is hoped the research will result in stem cells being used to repair damaged organs. Mr de Coppi has looked for naturally occurring stem cells in amniotic fluid as a novel solution to some of the serious birth defects he sees. Around 40 per cent of patients at Great Ormond Street Hospital have some form of birth defect.

Mr de Coppi said: “As a surgeon I often see the devastating effects of multiple reconstructive operations aimed at replacing damaged organs. I have therefore focused my research interests on stem cells and tissue engineering, trying to find new ways to treat complex birth defects. I have identified stem cells in the amniotic fluid and found they have the ability to become many different types of cell. Our research aims to find ways of using these cells to repair and replace damaged tissues, so that babies are given the chance of a healthy life from the day they are born.

“The idea is we can create tissues in a test tube using a baby’s own cells, and then implant these at birth. We’re looking at repairing organs like intestines or windpipes. Grown from a child’s own cells, there should be no rejection of tissue.”

The video sees Mr. de Coppi discussing the work he and his colleagues carry out and offering insight into the latest developments relating to his stem cell research and the possibility of deriving cells from amniotic fluid. The full video can be viewed here: http://www.youtube.com/watch?v=qD_V1hqR6SI.

Via EPR Network
More Healthcare press releases

Biotech, Disorders, Doctors, Drugs, Genetics, Health 2.0, Healthcare, Healthcare Professionals, Hospitals, Pharmaceuticals

Great Ormond Street Hospital Patients Take Part In Duchenne Muscular Dystrophy Clinical Trial

Leave a comment

Great Ormond Street Hospital has announced that a team led by scientists at its research partner, UCL Institute of Child Health (ICH), funded by the Medical Research Council (MRC) and AVI BioPharma, have made an important breakthrough in the development of a treatment for Duchenne Muscular Dystrophy (DMD).

Together with the MDEX Consortium, chaired by the ICH’s Professor Francesco Muntoni, the group showed that a gene based drug treatment was effective in restoring the dystrophin protein, missing in sufferers of DMD in seven out of 19 trial participants.

The results of the clinical trial will be published in The Lancet, a world leading general medical journal.

DMD is a devastating and life limiting condition, affecting one in 3,500 male births in the general population, with around 100 cases diagnosed in the UK each year.

Three of the participants in the higher dose cohort showed dystrophin levels exceeding 18 per cent of those found in normal muscle.

Thirteen per cent of boys with DMD could be treated with this specific ‘antisense’ gene therapy, the largest group by a single antisense. Overall, scientists say this approach could work for at least 70 per cent of DMD sufferers.

DMD causes progressive muscle weakness due to the breakdown and loss of muscle cells. Patients lack a single important protein in their muscle fibres called dystrophin. By ages eight to 12 years boys become unable to walk, and by their late teens or early twenties the condition can become severe enough to limit life expectancy.

In this clinical trial of 19 patients, study participants aged five to 15 at Great Ormond Street Hospital and the Royal Victoria Infirmary, Newcastle, were given weekly doses of the drug, AVI-4658. The drug had already been tested for safety and efficacy by the MDEX Consortium and AVI Biopharma in an earlier phase of the study.

Francesco Muntoni, professor of paediatric neurology at the ICH, said: “These are very exciting results that prove the case for an even more detailed look at this genetic therapy. I’ve worked with patients with DMD for many years and this is the first time we can say with confidence that we’ve made a significant breakthrough towards finding a targeted treatment.

“Importantly, the study drug was extremely well tolerated, with no appreciable side effects detected during the study period in any of the boys. If our strategy shows continued success, this therapy could substantially reduce muscle damage in affected boys with DMD, improve the quality of life for DMD patients, their mobility and the way their condition is managed as they get older.”

Professor Max Parmar, director of the MRC Clinical Trials Unit, said: “A large proportion of new drugs do not make it past the phase II stage of testing reached here, so there is real excitement that this treatment could work.

Brothers Jack, 11, and Tom, 8 were enrolled on the trial. Both have DMD with a deletion from 45-50. Their mum, Claire, said: “Jack and Tom were placed on a DMD genetic registry, co-ordinated by Action Duchenne, which is how we were approached about the clinical trial at Great Ormond Street Hospital.

“The boys were on the trial for 12 weeks between 2009 and 2010. Our whole family noticed a marked difference in both of their quality of life and mobility over that period. We feel that it helped prolong Jack’s mobility and that Tom has been considerably less fatigued.”

Via EPR Network
More Healthcare press releases

Consultations, Courses, Disorders, Healthcare, Healthcare Information, Healthcare Professionals, Healthcare Services, Psychiatry, Psychologist, Society, Therapies

Women’s Level One Weekend Mindfulness Retreat, Rome, GA: June 17-19, 2011

Leave a comment

“It’s almost normal today to feel as if you have ADD (Attention Deficit Disorder). We’re all suffering from stimulation overload and sensory exhaustion” says Pamela Barge, MS, LPC, NCC, Director of Personal Coaching & Psychotherapy Associates, LLC dba Personal Coaching & Psychotherapy for Women. This is what led Pam to put together her special weekend mindfulness retreats which she offers to professional colleagues as sanctioned continuing education programs as well as to the general public.

“These special weekends are offered as a special time away…a time to check out from the world and into ourselves for a time”. With sunrise and candlelight yoga, tai chi, delicious plant based meals, mindful consideration of what the Buddhists call ‘Noble Silence’, opportunities to practice sitting and walking meditation as well as stimulating group discussions with like-minded folks, this may be just the ticket to slow things down and to become more connected with yourself and with life.

Pamela Barge, LPC, has a background as a marketing executive and independent entrepreneur. This business background together with her training as a therapist and her own practice of mindful meditation gives her therapy and coaching practice its unique flavor. The theoretical foundation of her work is founded upon the tenets of mindfulness and the evidence-based works of such folks as Jon Kabat Zinn, PhD, founder of the Stress Reduction Clinic at the University of Massachusetts, Thich Nhat Hanh, world renowned and revered Buddhist monk who was nominated for the Nobel Peace Prize by Martin Luther King, Sharon Salzberg of the Insight Meditation Society in Barre, Massachusetts and His Holiness the XIV Dalai Lama.

Each retreat is limited to fifteen attendees. For more information, to see an individual retreat schedule as well as her 2011 Retreat Calendar or to make a reservation, visit her website at www.womenscoaching.biz or phone Pam at 678-230-8127.

Via EPR Network
More Healthcare press releases

Clinics, Consultations, Disorders, Healthcare, Healthcare Professionals, Healthcare Services, Rehab, Society, Therapies

Holistic Healing Is Key In Bulimia Treatment

Many bulimia treatment centers offer recovery programs to their clients. But few of them devote adequate resources to the bulimia disorder recovery process. In fact, many of the most “exclusive” bulimia treatment facilities in Los Angeles provide patients with grossly inferior bulimia treatment services. As should go without saying, you can’t afford to trust your health to one of these institutions.

Holistic Healing Is Key In Bulimia Treatment

Bulimia ruins lives. Bulimia treatment can help to solve the problem, but only if it’s administered by people who know exactly what they’re doing. Those bulimia treatment facilities which employ inexperienced or unqualified therapists do an enormous disservice to patients and their families. Here’s hoping you won’t have to learn that truth the hard way.

The most successful bulimia treatment center in Malibu is also one of California’s most distinguished treatment clinics. The reason is simple: The center’s bulimia treatment specialists are leading figures in their respective fields. Their expertise has helped countless clients achieve meaningful and lasting recovery. Don’t wait any longer to include yourself among the lucky few.

Via EPR Network
More Healthcare press releases

Alternative medicine, Consultations, Courses, Disorders, Health Products, Healthcare, Healthcare Information, Healthcare Professionals, Healthcare Services

Non-Invasive Procedures Help Reduce Frozen Shoulder Syndrome

Get ready for a pain-free life if you’ve been suffering for years from a frozen shoulder. Adhesive capsulitis plagues hundreds of thousands of people every day, but now victims finally have hope. Who knew you could lead a pain-free life with the help of just two books, an exercise band and a DVD? It’s time to stop living in the dark ages and embrace the science of the twenty first century, letting the Neil-Asher technique lead the way.

Non-Invasive Procedures Help Reduce Frozen Shoulder Syndrome

The unique aspect of this technique focuses on the body’s ability and capacity to heal itself. It’s the most basic way of healing your body and its secret lies in its simple way of thinking. Healing is not dependent on drugs or surgery; this method works by stimulating new pathways in the brain, rapidly reducing injury and spasms, and increasing strength and power. Using a varied set and a specific sequence of manipulations and pressure points of the shoulder joints and soft-tissues, it’s a hands-on holistic form of healing. In effect, what it does is ‘fool’ your brain and therefore your body into healing itself.

Where physical therapy tries to improve the range of motion by forcing the shoulder through the blockage, the Niel-Asher technique is a method of natural sequences of applying pressure to specific points, which eases the stress and pain. When we get shoulder injuries, the brain responds by ‘switching off’ normal muscular co-ordination. There are a number of problems that arise when this happens, and the chief and most common one is a frozen shoulder. The Niel-Asher technique works by stimulating a sequence of reflexes and sending new messages to the brain.

The frozen shoulder syndrome might start off as a niggling pain that can build up to stiff joints and ultimately partial immobility. Steroids and operations have had little or no effect and this is where the natural and holistic method of Mr Simeon Niel Asher proves to be a winner, guaranteeing at least 80 percent reduction in shoulder joint pain.

What starts off as a minor muscle pull could debilitate into something more painful and agonising. Instead you can let the power of nature heal you, and let your body take charge. Niel-Asher’s books and accompanying DVD guide are easy to follow, and have proven to be effective in reduction of pain. Why live in pain when there is a solution that is safe, non-invasive, and proven to relieve your discomfort and suffering? There isn’t much you have to do except follow the technique and let trained therapists help you lead a healthier life.

Via EPR Network
More Healthcare press releases

Clinics, Consultations, Disorders, Healthcare, Healthcare Professionals, Healthcare Services, Rehab, Society, Therapies

The Leading Eating Disorder Treatment Centers In California

Many eating disorder treatment centers offer programs to their clients. But few of them devote adequate resources to the eating disorders treatment process. In fact, many of the most “exclusive” eating disorder treatment centers in Los Angeles provide patients with a grossly inferior eating disorder treatment program. As should go without saying, you can’t afford to trust your health to one of these institutions.

The Leading Eating Disorder Treatment Centers In California

Anorexia and bulimia ruin lives. Eating disorder treatment centers can help to solve the problem, but only if it’s administered by people who know exactly what they’re doing. Those eating disorder treatment centers which employ inexperienced or unqualified eating disorder therapists do an enormous disservice to patients and their families. Here’s hoping you won’t have to learn that truth the hard way.

The most successful eating disorder treatment center in Malibu is also one of California’s most distinguished eating disorder treatment centers. The reason is simple: The center’s eating disorder treatment specialists are leading figures in their respective fields. Their expertise has helped countless clients achieve meaningful and lasting recovery. Don’t wait any longer to include yourself among the lucky few.

Via EPR Network
More Healthcare press releases